Gregory W. Roloff, MD, on Assessing Real-World Experience of Brexu-Cel in Adults With B-ALL
The chief hematology/oncology fellow at University of Chicago discussed new data from the ROCCA collaborative study presented at ASH 2023.
“Adult patients with acute lymphoblastic leukemia have experienced improved outcomes in recent years but relapse is still a very common occurrence. Even now we have newer agents...immune based therapies, that had really revolutionized the care of these patients, but relapse is still a problem and the duration of remission that those new therapies provide is not as long as we would hope it to be.”
Adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with commercial brexucabtagene autoleucel (Tecartus; Kite) across US sites had a 90% complete response rate and 82% minimal residual disease negativity rate, according to the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) study. Investigators saw low rates of severe cytokine release syndrome but a 32% rate of grade 3-4 immune effector cell-associated neurotoxicity syndrome.
The new data from ROCCA were presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, held December 9-12, in San Diego, California, by Gregory Roloff, MD, chief hematology/oncology fellow, University of Chicago.
CGTLive spoke with Roloff to learn more about the background of the ROCCA study. He discussed the 2021 approval of brexu-cel and how it changed the treatment landscape but emphasized the need to understand the real-world experience of patients receiving, orattempting to receive the chimeric antigen receptor (CAR) T-cell therapy.
